This article is more than 5 years old. Information may no longer be current.

VIDEO: Gene alterations predict response to immunotherapy in urothelial carcinoma

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Alterations in DNA damage repair and response genes appear to improve response to immune checkpoint blockade among patients with urothelial carcinoma, according to findings presented at the ASCO Annual Meeting.

These results “clearly” indicate that such alternations could be “a potential predictive biomarker for response to immune checkpoint blockade,” according to Matthew Galsky, MD, professor of medicine (hematology and medical oncology) and urology at the Icahn School of Medicine at Mount Sinai Hospital in New York.

“This is not ready for prime time, but there are ongoing, randomized clinical trials in the first-line setting in urothelial cancer, randomizing patients to chemotherapy alone vs. chemotherapy plus immune checkpoint blockade,” Galsky said. “Those cohorts are ideally suited for testing this biomarker question.”